The EpiSwitch CST was developed by Oxford BioDynamics, a leader in the design of genomic tests that help people understand their disease risks and likely response to prescribed drugs.
Research and development of EpiSwitch, a unique biomarker discovery platform based on 3D genomics, began at Oxford University, England in 2005. Following the successful validation of the predictive accuracy of the platform in June 2007, a new company, Oxford BioDynamics, was spun out of the University. Since its inception, Oxford Biodynamics’ mission has been to leverage the EpiSwitch platform to develop a novel class of precision tests for cancer and chronic illnesses.
The EpiSwitch platform was recognized by Frost & Sullivan as the Best European Biomarker Discovery Technology in 2015 and the company was a recipient of the 2019 Queen’s Awards for Enterprise in Innovation. EpiSwitch is poised to play a critical role in identifying individual disease risk profiles to optimize the diagnosis and management of a range of conditions and diseases to help advance personalized healthcare.